RecruitingNCT06940674
Cannabidiol added to care for opioid use disorder
About this title
Read the official source — NCT06940674Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
For the opioid-use study, participants maintained on opioid agonist treatment are randomly assigned to CBD or placebo (an inactive comparison treatment). The registered groups take their assigned capsules twice daily at either the lower or higher CBD dose. The study examines craving and anxiety; the earlier healthy-volunteer phase is a separate part of the project.
- Listed locations
- New York and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 13, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 450
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06940674
- Official title
Show the full official title
Adjunctive Cannabidiol for Recovery From Opioid Study (ACROS)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New York · Portland
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
